RecruitingPhase 1NCT06752122

Safety, Tolerability, and Pharmacokinetics of RCS-21 in Healthy Volunteers.

Safety, Tolerability and Pharmacokinetics of Single-ascending Doses of RCS-21 in Healthy Volunteers. A Double Blind, Randomized, Placebo Controlled Phase I Study.

Sponsor

RNATICS GmbH

Enrollment

24 participants

Start Date

Feb 18, 2025

Study Type

INTERVENTIONAL

Conditions

Safety Healthy Volunteers Tolerability Pharmacokinetics

Summary

The goal of this clinical trial is to evaluate the safety and tolerability of RCS-21 in healthy volunteers. Participants will be asked to inhale a single dose of RCS-21 and their health status will be constantly monitored.

Eligibility

Min Age: 18 YearsMax Age: 64 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Placebo (SAD) and a drug called RCS-21 (SAD) for people with healthy volunteers, pharmacokinetics, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 64 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.